- Home
- NTRA vs SSNC Comparison
NTRA vs SSNC Comparison
Compare NTRA & SSNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- SSNC
- Stock Information
- Founded
- NTRA 2003
- SSNC 1986
- Country
- NTRA United States
- SSNC United States
- Employees
- NTRA N/A
- SSNC N/A
- Industry
- NTRA Medical Specialities
- SSNC EDP Services
- Sector
- NTRA Health Care
- SSNC Technology
- Exchange
- NTRA Nasdaq
- SSNC Nasdaq
- Market Cap
- NTRA 18.4B
- SSNC 20.3B
- IPO Year
- NTRA 2015
- SSNC 1996
- Fundamental
- Price
- NTRA $143.94
- SSNC $81.98
- Analyst Decision
- NTRA Strong Buy
- SSNC Strong Buy
- Analyst Count
- NTRA 17
- SSNC 6
- Target Price
- NTRA $179.00
- SSNC $99.50
- AVG Volume (30 Days)
- NTRA 1.9M
- SSNC 1.5M
- Earning Date
- NTRA 05-08-2025
- SSNC 04-24-2025
- Dividend Yield
- NTRA N/A
- SSNC 1.23%
- EPS Growth
- NTRA N/A
- SSNC 25.52
- EPS
- NTRA N/A
- SSNC 3.00
- Revenue
- NTRA $1,696,911,000.00
- SSNC $5,882,000,000.00
- Revenue This Year
- NTRA $13.56
- SSNC $7.38
- Revenue Next Year
- NTRA $18.11
- SSNC $5.05
- P/E Ratio
- NTRA N/A
- SSNC $27.21
- Revenue Growth
- NTRA 56.75
- SSNC 6.89
- 52 Week Low
- NTRA $83.13
- SSNC $59.63
- 52 Week High
- NTRA $183.00
- SSNC $89.73
- Technical
- Relative Strength Index (RSI)
- NTRA 41.35
- SSNC 42.72
- Support Level
- NTRA $146.35
- SSNC $82.25
- Resistance Level
- NTRA $155.64
- SSNC $84.46
- Average True Range (ATR)
- NTRA 6.42
- SSNC 1.60
- MACD
- NTRA 0.87
- SSNC -0.03
- Stochastic Oscillator
- NTRA 51.93
- SSNC 48.97
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About SSNC SS&C Technologies Holdings Inc.
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.